Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006.

Shares in financial firm Stifel (SF) dropped 3% today after it was told to cough up $132.5 million in damages to a U.S.

SPDR ® S&P Biotech ETF earns an Average Process Pillar rating. Morningstar's algorithmically assigned Passive Process ratings are first formulated by comparing the historical efficacy of passive ...

Ieq Capital LLC lowered its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 7.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and ...

Fintel reports that on March 12, 2025, Evercore ISI Group initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a ...

Kingsview Wealth Management LLC lifted its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 60.3% during the fourth quarter, according to the company in its most recent filing ...

Short interest in SPDR Series Trust SPDR S&P Biotech ETF (ARCA:XBI) decreased during the last reporting period, falling from 58.01M to 56.14M. This put -% of the company's publicly available ...

The SPDR S&P Dividend ETF offers a hybrid strategy split between high dividend yield and dividend growth stocks.

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. The ETF industry has ...